Company Overview

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. We market a portfolio of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus area.

We use revenue from sales of our marketed products to fund a significant portion of the development costs of other product candidates and the expansion of the Company’s sales and marketing infrastructure. We develop product candidates primarily through the application of proprietary drug delivery and formulation technologies to known drug compounds in pain management and potentially other complementary therapeutic areas.

Recently Approved: Zipsor^® for the treatment of mild to moderate acute pain in adults was approved by the FDA on June 16, 2009. Lysteda™ was approved following a Priority Review by the FDA for the treatment of cyclic heavy menstrual bleeding on November 13, 2009. Lysteda was sold to Ferring Pharmaceuticals in May, 2010.

We are Developing: XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S. XP21B for the treatment of acute pain is in Phase 2 development.

We currently have an integrated commercial organization to market and sell our in-market products. This organization includes a U.S. specialty sales force that calls on both specialists and primary care physicians.

We are led by an executive team with substantial experience in identifying, developing and commercializing significant new products at other specialty pharmaceutical companies.